I agree with all the positive comments. The company has placed itself in an exciting and protected position. Most early concerns regarding the technology and cash position are fading away and in its place is years of experiential growth and upside. Clever IP strategy agree, validation of the science tick, associations and growth pathways identified, current and future products in diverse market applications.. yes. All this in the rapidly growing emerging global market place of biotech. This will be special.
